These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24755198)

  • 21. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
    Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas: Toward Genetic Distinctions of Animal-type Melanoma/Pigment Synthesizing Melanoma.
    Cohen JN; Yeh I; Mully TW; LeBoit PE; McCalmont TH
    Am J Surg Pathol; 2020 Jun; 44(6):805-816. PubMed ID: 32118628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma genomics - will we go beyond BRAF in clinics?
    Mirek J; Bal W; Olbryt M
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):433. PubMed ID: 39340537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
    Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
    BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular profile of mucosal melanoma.
    Mikkelsen LH; Maag E; Andersen MK; Kruhøffer M; Larsen AC; Melchior LC; Toft PB; von Buchwald C; Wadt K; Heegaard S
    Melanoma Res; 2020 Dec; 30(6):533-542. PubMed ID: 33156594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
    Urso C
    Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
    Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
    J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations.
    Lehmann BD; Shaver TM; Johnson DB; Li Z; Gonzalez-Ericsson PI; Sánchez V; Shyr Y; Sanders ME; Pietenpol JA
    Mol Cancer Res; 2019 Sep; 17(9):1842-1853. PubMed ID: 31186280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
    Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
    Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    Moon KR; Choi YD; Kim JM; Jin S; Shin MH; Shim HJ; Lee JB; Yun SJ
    J Invest Dermatol; 2018 Apr; 138(4):933-945. PubMed ID: 29191620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and genetic analysis of melanomas arising in acral sites.
    Zaremba A; Murali R; Jansen P; Möller I; Sucker A; Paschen A; Zimmer L; Livingstone E; Brinker TJ; Hadaschik E; Franklin C; Roesch A; Ugurel S; Schadendorf D; Griewank KG; Cosgarea I
    Eur J Cancer; 2019 Sep; 119():66-76. PubMed ID: 31419753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of gene fusions in melanocytic neoplasms.
    Quan VL; Panah E; Zhang B; Shi K; Mohan LS; Gerami P
    J Cutan Pathol; 2019 Nov; 46(11):878-887. PubMed ID: 31152596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
    Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
    BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.